Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 150

1.

Mortality From Postscreening (Interval) Colorectal Cancers Is Comparable to That From Cancer in Unscreened Patients-A Randomized Sigmoidoscopy Trial.

Jodal HC, Løberg M, Holme Ø, Adami HO, Bretthauer M, Emilsson L, Ransohoff DF, Hoff G, Kalager M.

Gastroenterology. 2018 Dec;155(6):1787-1794.e3. doi: 10.1053/j.gastro.2018.08.035. Epub 2018 Aug 27.

PMID:
30165051
2.

Screening for Colorectal Neoplasia.

Imperiale TF, Ransohoff DF.

N Engl J Med. 2017 Apr 20;376(16):1598-9. doi: 10.1056/NEJMc1702535. No abstract available.

PMID:
28425279
3.

Institutional Responsibility and the Flawed Genomic Biomarkers at Duke University: A Missed Opportunity for Transparency and Accountability.

DeMets DL, Fleming TR, Geller G, Ransohoff DF.

Sci Eng Ethics. 2017 Aug;23(4):1199-1205. doi: 10.1007/s11948-016-9844-4. Epub 2016 Nov 23.

PMID:
27882502
4.

Risk of Advanced Neoplasia Using the National Cancer Institute's Colorectal Cancer Risk Assessment Tool.

Imperiale TF, Yu M, Monahan PO, Stump TE, Tabbey R, Glowinski E, Ransohoff DF.

J Natl Cancer Inst. 2016 Aug 31;109(1). doi: 10.1093/jnci/djw181. Print 2017 Jan.

PMID:
27582444
5.

Clinical Practice Guidelines for Colorectal Cancer Screening: New Recommendations and New Challenges.

Ransohoff DF, Sox HC.

JAMA. 2016 Jun 21;315(23):2529-31. doi: 10.1001/jama.2016.7990. No abstract available.

PMID:
27304798
6.

Rationale and design of the European Polyp Surveillance (EPoS) trials.

Jover R, Bretthauer M, Dekker E, Holme Ø, Kaminski MF, Løberg M, Zauber AG, Hernán MA, Lansdorp-Vogelaar I, Sunde A, McFadden E, Castells A, Regula J, Quintero E, Pellisé M, Senore C, Kalager M, Dinis-Ribeiro M, Emilsson L, Ransohoff DF, Hoff G, Adami HO.

Endoscopy. 2016 Jun;48(6):571-8. doi: 10.1055/s-0042-104116. Epub 2016 Apr 4.

7.

Reply.

Imperiale TF, Ransohoff DF.

Gastroenterology. 2016 Apr;150(4):1037. doi: 10.1053/j.gastro.2016.02.053. Epub 2016 Feb 27. No abstract available.

PMID:
26926450
8.

Derivation and Validation of a Scoring System to Stratify Risk for Advanced Colorectal Neoplasia in Asymptomatic Adults: A Cross-sectional Study.

Imperiale TF, Monahan PO, Stump TE, Glowinski EA, Ransohoff DF.

Ann Intern Med. 2015 Sep 1;163(5):339-46. doi: 10.7326/M14-1720.

9.

Leveraging biospecimen resources for discovery or validation of markers for early cancer detection.

Schully SD, Carrick DM, Mechanic LE, Srivastava S, Anderson GL, Baron JA, Berg CD, Cullen J, Diamandis EP, Doria-Rose VP, Goddard KA, Hankinson SE, Kushi LH, Larson EB, McShane LM, Schilsky RL, Shak S, Skates SJ, Urban N, Kramer BS, Khoury MJ, Ransohoff DF.

J Natl Cancer Inst. 2015 Feb 16;107(4). pii: djv012. doi: 10.1093/jnci/djv012. Print 2015 Apr.

10.

Transparent Reporting of a multivariable prediction model for Individual Prognosis or Diagnosis (TRIPOD): explanation and elaboration.

Moons KG, Altman DG, Reitsma JB, Ioannidis JP, Macaskill P, Steyerberg EW, Vickers AJ, Ransohoff DF, Collins GS.

Ann Intern Med. 2015 Jan 6;162(1):W1-73. doi: 10.7326/M14-0698.

PMID:
25560730
11.

Multitarget stool DNA testing for colorectal-cancer screening.

Imperiale TF, Ransohoff DF, Itzkowitz SH.

N Engl J Med. 2014 Jul 10;371(2):187-8. doi: 10.1056/NEJMc1405215. No abstract available.

PMID:
25006736
12.

Addressing overdiagnosis and overtreatment in cancer: a prescription for change.

Esserman LJ, Thompson IM, Reid B, Nelson P, Ransohoff DF, Welch HG, Hwang S, Berry DA, Kinzler KW, Black WC, Bissell M, Parnes H, Srivastava S.

Lancet Oncol. 2014 May;15(6):e234-42. doi: 10.1016/S1470-2045(13)70598-9.

13.

Multitarget stool DNA testing for colorectal-cancer screening.

Imperiale TF, Ransohoff DF, Itzkowitz SH, Levin TR, Lavin P, Lidgard GP, Ahlquist DA, Berger BM.

N Engl J Med. 2014 Apr 3;370(14):1287-97. doi: 10.1056/NEJMoa1311194. Epub 2014 Mar 19.

14.

What is the effect of more sensitive diagnostic technology?

Ransohoff DF.

Lancet Oncol. 2014 Mar;15(3):256-7. doi: 10.1016/S1470-2045(14)70065-8. Epub 2014 Feb 20. No abstract available.

PMID:
24560454
15.

Endoscopic detection of proximal serrated lesions and pathologic identification of sessile serrated adenomas/polyps vary on the basis of center.

Payne SR, Church TR, Wandell M, Rösch T, Osborn N, Snover D, Day RW, Ransohoff DF, Rex DK.

Clin Gastroenterol Hepatol. 2014 Jul;12(7):1119-26. doi: 10.1016/j.cgh.2013.11.034. Epub 2013 Dec 10.

PMID:
24333512
16.

Guidelines for guidelines: measuring trustworthiness.

Ransohoff DF, Sox HC.

J Clin Oncol. 2013 Jul 10;31(20):2530-1. doi: 10.1200/JCO.2013.50.0462. Epub 2013 Jun 10. No abstract available.

PMID:
23752106
17.

Colon cancer screening models: lessons and challenges.

Ransohoff DF, Pignone M.

Clin Gastroenterol Hepatol. 2013 Sep;11(9):1167-8. doi: 10.1016/j.cgh.2013.04.041. Epub 2013 May 6. No abstract available.

PMID:
23660420
18.

Development of trustworthy practice guidelines--reply.

Ransohoff DF, Pignone M, Sox HC.

JAMA. 2013 May 8;309(18):1890-1. doi: 10.1001/jama.2013.3370. No abstract available.

PMID:
23652517
19.

Cultivating cohort studies for observational translational research.

Ransohoff DF.

Cancer Epidemiol Biomarkers Prev. 2013 Apr;22(4):481-4. doi: 10.1158/1055-9965.EPI-13-0140. Epub 2013 Mar 5.

20.

Transforming epidemiology for 21st century medicine and public health.

Khoury MJ, Lam TK, Ioannidis JP, Hartge P, Spitz MR, Buring JE, Chanock SJ, Croyle RT, Goddard KA, Ginsburg GS, Herceg Z, Hiatt RA, Hoover RN, Hunter DJ, Kramer BS, Lauer MS, Meyerhardt JA, Olopade OI, Palmer JR, Sellers TA, Seminara D, Ransohoff DF, Rebbeck TR, Tourassi G, Winn DM, Zauber A, Schully SD.

Cancer Epidemiol Biomarkers Prev. 2013 Apr;22(4):508-16. doi: 10.1158/1055-9965.EPI-13-0146. Epub 2013 Mar 5.

21.

How can polygenic inheritance be used in population screening for common diseases?

Khoury MJ, Janssens AC, Ransohoff DF.

Genet Med. 2013 Jun;15(6):437-43. doi: 10.1038/gim.2012.182. Epub 2013 Feb 14. Review.

22.

Prospective evaluation of methylated SEPT9 in plasma for detection of asymptomatic colorectal cancer.

Church TR, Wandell M, Lofton-Day C, Mongin SJ, Burger M, Payne SR, Castaños-Vélez E, Blumenstein BA, Rösch T, Osborn N, Snover D, Day RW, Ransohoff DF; PRESEPT Clinical Study Steering Committee, Investigators and Study Team.

Gut. 2014 Feb;63(2):317-25. doi: 10.1136/gutjnl-2012-304149. Epub 2013 Feb 13.

23.

How to decide whether a clinical practice guideline is trustworthy.

Ransohoff DF, Pignone M, Sox HC.

JAMA. 2013 Jan 9;309(2):139-40. doi: 10.1001/jama.2012.156703. No abstract available.

PMID:
23299601
24.

Tailoring colorectal cancer screening by considering risk of advanced proximal neoplasia.

Imperiale TF, Glowinski EA, Lin-Cooper C, Ransohoff DF.

Am J Med. 2012 Dec;125(12):1181-7. doi: 10.1016/j.amjmed.2012.05.026. Epub 2012 Oct 9.

25.

Risk for colorectal cancer in persons with a family history of adenomatous polyps: a systematic review.

Imperiale TF, Ransohoff DF.

Ann Intern Med. 2012 May 15;156(10):703-9. doi: 10.7326/0003-4819-156-10-201205150-00006. Review.

PMID:
22586009
26.

Bone-density testing interval and transition to osteoporosis in older women.

Gourlay ML, Fine JP, Preisser JS, May RC, Li C, Lui LY, Ransohoff DF, Cauley JA, Ensrud KE; Study of Osteoporotic Fractures Research Group.

N Engl J Med. 2012 Jan 19;366(3):225-33. doi: 10.1056/NEJMoa1107142.

27.

Using models to make policy: an inflection point?

Ransohoff DF, Pignone M, Russell LB.

Med Decis Making. 2011 Jul-Aug;31(4):527-9. doi: 10.1177/0272989X11412079. No abstract available.

PMID:
21757648
28.

Cross-model comparisons to improve the value of modeling: the case of colorectal cancer screening.

Pignone M, Ransohoff DF.

Med Decis Making. 2011 Jul-Aug;31(4):524-6. doi: 10.1177/0272989X11412195. No abstract available.

PMID:
21757647
29.

Recommendations for post-polypectomy surveillance in community practice.

Ransohoff DF, Yankaskas B, Gizlice Z, Gangarosa L.

Dig Dis Sci. 2011 Sep;56(9):2623-30. doi: 10.1007/s10620-011-1791-y. Epub 2011 Jun 23.

30.

A framework for evaluating biomarkers for early detection: validation of biomarker panels for ovarian cancer.

Zhu CS, Pinsky PF, Cramer DW, Ransohoff DF, Hartge P, Pfeiffer RM, Urban N, Mor G, Bast RC Jr, Moore LE, Lokshin AE, McIntosh MW, Skates SJ, Vitonis A, Zhang Z, Ward DC, Symanowski JT, Lomakin A, Fung ET, Sluss PM, Scholler N, Lu KH, Marrangoni AM, Patriotis C, Srivastava S, Buys SS, Berg CD; PLCO Project Team.

Cancer Prev Res (Phila). 2011 Mar;4(3):375-83. doi: 10.1158/1940-6207.CAPR-10-0193.

31.

Biomarker studies: a call for a comprehensive biomarker study registry.

Andre F, McShane LM, Michiels S, Ransohoff DF, Altman DG, Reis-Filho JS, Hayes DF, Pusztai L.

Nat Rev Clin Oncol. 2011 Mar;8(3):171-6. doi: 10.1038/nrclinonc.2011.4. Review.

PMID:
21364690
32.

Flexible sigmoidoscopy to prevent colorectal cancer.

Doria-Rose VP, Vinden C, Ransohoff DF, Prorok PC.

Lancet. 2010 Sep 11;376(9744):871; author reply 871-2. doi: 10.1016/S0140-6736(10)61407-9. No abstract available.

PMID:
20833296
33.

Principles of cancer screening: lessons from history and study design issues.

Croswell JM, Ransohoff DF, Kramer BS.

Semin Oncol. 2010 Jun;37(3):202-15. doi: 10.1053/j.seminoncol.2010.05.006. Review.

34.

Can endoscopy protect against colorectal cancer? An RCT.

Ransohoff DF.

Lancet. 2010 May 8;375(9726):1582-4. doi: 10.1016/S0140-6736(10)60626-5. Epub 2010 Apr 27. No abstract available.

PMID:
20430430
35.

Understanding differences in the guidelines for colorectal cancer screening.

Imperiale TF, Ransohoff DF.

Gastroenterology. 2010 May;138(5):1642-1647.e1. doi: 10.1053/j.gastro.2010.03.027. Epub 2010 Mar 16.

PMID:
20302867
36.

Personal genomics: information can be harmful.

Ransohoff DF, Khoury MJ.

Eur J Clin Invest. 2010 Jan;40(1):64-8. doi: 10.1111/j.1365-2362.2009.02232.x. No abstract available.

PMID:
20055897
37.

Proteomics research to discover markers: what can we learn from Netflix?

Ransohoff DF.

Clin Chem. 2010 Feb;56(2):172-6. doi: 10.1373/clinchem.2009.126698. Epub 2009 Dec 29. Review.

38.

Sources of bias in specimens for research about molecular markers for cancer.

Ransohoff DF, Gourlay ML.

J Clin Oncol. 2010 Feb 1;28(4):698-704. doi: 10.1200/JCO.2009.25.6065. Epub 2009 Dec 28.

39.

Analytical validation of protein-based multiplex assays: a workshop report by the NCI-FDA interagency oncology task force on molecular diagnostics.

Rodriguez H, Tezak Z, Mesri M, Carr SA, Liebler DC, Fisher SJ, Tempst P, Hiltke T, Kessler LG, Kinsinger CR, Philip R, Ransohoff DF, Skates SJ, Regnier FE, Anderson NL, Mansfield E; Workshop Participants.

Clin Chem. 2010 Feb;56(2):237-43. doi: 10.1373/clinchem.2009.136416. Epub 2009 Dec 10. Review.

40.

Protein-based multiplex assays: mock presubmissions to the US Food and Drug Administration.

Regnier FE, Skates SJ, Mesri M, Rodriguez H, Tezak Z, Kondratovich MV, Alterman MA, Levin JD, Roscoe D, Reilly E, Callaghan J, Kelm K, Brown D, Philip R, Carr SA, Liebler DC, Fisher SJ, Tempst P, Hiltke T, Kessler LG, Kinsinger CR, Ransohoff DF, Mansfield E, Anderson NL.

Clin Chem. 2010 Feb;56(2):165-71. doi: 10.1373/clinchem.2009.140087. Epub 2009 Dec 10.

41.

Pragmatic classification of superficial neoplastic colorectal lesions.

Lambert R, Kudo SE, Vieth M, Allen JI, Fujii H, Fujii T, Kashida H, Matsuda T, Mori M, Saito H, Shimoda T, Tanaka S, Watanabe H, Sung JJ, Feld AD, Inadomi JM, O'Brien MJ, Lieberman DA, Ransohoff DF, Soetikno RM, Zauber A, Teixeira CR, Rey JF, Jaramillo E, Rubio CA, Van Gossum A, Jung M, Jass JR, Triadafilopoulos G.

Gastrointest Endosc. 2009 Dec;70(6):1182-99. doi: 10.1016/j.gie.2009.09.015. Epub 2009 Oct 31. No abstract available.

PMID:
19879563
42.

The Scientific Foundation for personal genomics: recommendations from a National Institutes of Health-Centers for Disease Control and Prevention multidisciplinary workshop.

Khoury MJ, McBride CM, Schully SD, Ioannidis JP, Feero WG, Janssens AC, Gwinn M, Simons-Morton DG, Bernhardt JM, Cargill M, Chanock SJ, Church GM, Coates RJ, Collins FS, Croyle RT, Davis BR, Downing GJ, Duross A, Friedman S, Gail MH, Ginsburg GS, Green RC, Greene MH, Greenland P, Gulcher JR, Hsu A, Hudson KL, Kardia SL, Kimmel PL, Lauer MS, Miller AM, Offit K, Ransohoff DF, Roberts JS, Rasooly RS, Stefansson K, Terry SF, Teutsch SM, Trepanier A, Wanke KL, Witte JS, Xu J; Centers for Disease Control and Prevention.

Genet Med. 2009 Aug;11(8):559-67. doi: 10.1097/GIM.0b013e3181b13a6c.

43.

Adverse events after outpatient colonoscopy in the Medicare population.

Warren JL, Klabunde CN, Mariotto AB, Meekins A, Topor M, Brown ML, Ransohoff DF.

Ann Intern Med. 2009 Jun 16;150(12):849-57, W152.

PMID:
19528563
44.

Variation in polyp detection rates at screening colonoscopy.

Imperiale TF, Glowinski EA, Juliar BE, Azzouz F, Ransohoff DF.

Gastrointest Endosc. 2009 Jun;69(7):1288-95. doi: 10.1016/j.gie.2007.11.043.

PMID:
19481649
45.

Promises and limitations of biomarkers.

Ransohoff DF.

Recent Results Cancer Res. 2009;181:55-9. Review.

PMID:
19213557
46.

How much does colonoscopy reduce colon cancer mortality?

Ransohoff DF.

Ann Intern Med. 2009 Jan 6;150(1):50-2. Epub 2008 Dec 15. No abstract available.

PMID:
19075200
47.

The process to discover and develop biomarkers for cancer: a work in progress.

Ransohoff DF.

J Natl Cancer Inst. 2008 Oct 15;100(20):1419-20. doi: 10.1093/jnci/djn339. Epub 2008 Oct 7. No abstract available.

PMID:
18840815
48.

Nonpolypoid neoplastic lesions of the colorectal mucosa.

Kudo Se, Lambert R, Allen JI, Fujii H, Fujii T, Kashida H, Matsuda T, Mori M, Saito H, Shimoda T, Tanaka S, Watanabe H, Sung JJ, Feld AD, Inadomi JM, O'Brien MJ, Lieberman DA, Ransohoff DF, Soetikno RM, Triadafilopoulos G, Zauber A, Teixeira CR, Rey JF, Jaramillo E, Rubio CA, Van Gossum A, Jung M, Vieth M, Jass JR, Hurlstone PD.

Gastrointest Endosc. 2008 Oct;68(4 Suppl):S3-47. doi: 10.1016/j.gie.2008.07.052. Review. No abstract available.

PMID:
18805238
49.

Five-year risk of colorectal neoplasia after negative screening colonoscopy.

Imperiale TF, Glowinski EA, Lin-Cooper C, Larkin GN, Rogge JD, Ransohoff DF.

N Engl J Med. 2008 Sep 18;359(12):1218-24. doi: 10.1056/NEJMoa0803597. Erratum in: N Engl J Med. 2009 Nov 12;361(20):2004.

50.

Implications of new colorectal cancer screening technologies for primary care practice.

Zauber AG, Levin TR, Jaffe CC, Galen BA, Ransohoff DF, Brown ML.

Med Care. 2008 Sep;46(9 Suppl 1):S138-46. doi: 10.1097/MLR.0b013e31818192ef. Review. No abstract available.

Supplemental Content

Loading ...
Support Center